Your browser doesn't support javascript.
loading
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg, Carin A T C; Henricks, Linda M; Dreussi, Eva; Peters, Femke P; Fiocco, Marta; Meulendijks, Didier; Toffoli, Giuseppe; Guchelaar, Henk-Jan; Swen, Jesse J; Cecchin, Erika; Schellens, Jan H M; Gelderblom, Hans.
Afiliação
  • Lunenburg CATC; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Henricks LM; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Dreussi E; Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, Italy.
  • Peters FP; Department of Radiotherapy, Leiden University Medical Centre, Leiden, The Netherlands.
  • Fiocco M; Medical Statistics, Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands; Mathematical Institute, Leiden University, The Netherlands.
  • Meulendijks D; Dutch Medicines Evaluation Board (CBG-MEB), Utrecht, The Netherlands.
  • Toffoli G; Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, Italy.
  • Guchelaar HJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Swen JJ; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Cecchin E; Experimental and Clinical Pharmacology Unit, National Cancer Institute, Aviano, Italy.
  • Schellens JHM; Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Pharmacoepidemiology & Clinical Pharmacology, Department of Pharmac
  • Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. Electronic address: A.J.Gelderblom@lumc.nl.
Eur J Cancer ; 104: 210-218, 2018 11.
Article em En | MEDLINE | ID: mdl-30361102
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Di-Hidrouracila Desidrogenase (NADP) / Deficiência da Di-Hidropirimidina Desidrogenase / Quimiorradioterapia / Capecitabina / Fluoruracila / Gastroenteropatias / Doenças Hematológicas / Proteínas de Neoplasias / Neoplasias / Antimetabólitos Antineoplásicos Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Di-Hidrouracila Desidrogenase (NADP) / Deficiência da Di-Hidropirimidina Desidrogenase / Quimiorradioterapia / Capecitabina / Fluoruracila / Gastroenteropatias / Doenças Hematológicas / Proteínas de Neoplasias / Neoplasias / Antimetabólitos Antineoplásicos Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda